A tumor-cell biomimetic nanoplatform embedding biological enzymes for enhanced metabolic therapy

2021 ◽  
Author(s):  
Ping Ji ◽  
Tian-Yang Wang ◽  
Guo-Feng Luo ◽  
Wei-Hai Chen ◽  
Xian-Zheng Zhang
Keyword(s):  
Cell Membrane ◽  
Tumor Cell ◽  
Glucose Oxidase ◽  
Therapeutic System ◽  
Zeolitic Imidazolate Framework ◽  
Tumor Cell Membrane ◽  
Metabolic Therapy

A tumor cell membrane-camouflaged therapeutic system was fabricated to eliminate tumors by embedding the Apyrase and glucose oxidase (GOx) into zeolitic imidazolate framework-8 (ZIF-8) nanoparticles for tumor-targeted metabolic therapy. Experimental...

Tumor cell membrane-targeting pH-dependent electron donor-acceptor fluorescence systems with low background signals

Biomaterials ◽  
2014 ◽  
Vol 35 (9) ◽  
pp. 2952-2960 ◽  
Author(s):  
Liang Han ◽  
Mingming Liu ◽  
Deyong Ye ◽  
Ning Zhang ◽  
Ed Lim ◽  
...  
Keyword(s):  
Cell Membrane ◽  
Tumor Cell ◽  
Electron Donor ◽  
Membrane Targeting ◽  
Tumor Cell Membrane ◽  
Low Background ◽  
Donor Acceptor ◽  
Ph Dependent

Tumor cell membrane enveloped aluminum phosphate nanoparticles for enhanced cancer vaccination

2020 ◽  
Vol 326 ◽  
pp. 297-309 ◽  
Author(s):  
Jingyao Gan ◽  
Guangsheng Du ◽  
Chunting He ◽  
Min Jiang ◽  
Xingyue Mou ◽  
...  
Keyword(s):  
Cell Membrane ◽  
Tumor Cell ◽  
Aluminum Phosphate ◽  
Tumor Cell Membrane ◽  
Cancer Vaccination

Tumor Cell Membrane‐Coated Liquid Metal Nanovaccine for Tumor Prevention ǂ

2020 ◽  
Vol 38 (6) ◽  
pp. 595-600
Author(s):  
Yu Zhang ◽  
Miao‐Deng Liu ◽  
Chu‐Xin Li ◽  
Bin Li ◽  
Xian‐Zheng Zhang
Keyword(s):  
Cell Membrane ◽  
Liquid Metal ◽  
Tumor Cell ◽  
Tumor Cell Membrane ◽  
Tumor Prevention

The expression and clinical significance of PD-L1 in patients with upper tract urothelial carcinoma.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 444-444
Author(s):  
Xinan Sheng ◽  
Zhisong He ◽  
Yan Kong ◽  
Zhihong Chi ◽  
Lu Si ◽  
...  
Keyword(s):  
Cell Membrane ◽  
Tumor Cell ◽  
Urothelial Carcinoma ◽  
Tumor Staging ◽  
Prognostic Significance ◽  
Upper Tract Urothelial Carcinoma ◽  
Tumor Cell Membrane ◽  
Upper Tract ◽  
Bladder Urothelial Carcinoma ◽  
N Classification

444 Background: Primary upper tract urothelial carcinoma (UTUC) is rare. In China UTUCs are more common than in Western populations and account for 20–30% of all TCCs.An antibody that targets programmed death ligand-1 (PD-L1) pathway has been shown to be active towards various types of cancer including bladder urothelial carcinoma. In this study, we investigated the PD-L1 expression and prognostic significance in UTUC. Methods: Formalin-fixed paraffin-embedded tumor samples from 78 patients with upper tract urothelial carcinoma from Peking University Cancer Hospital and Peking Universiy First Hospital were retrieved. PD-L1 expression was evaluated by immunohistochemistry using rabbit monoclonal anti-PD-L1 antibody. PD-L1 positivity on tumor cell membrane was defined as ≥ 1% of tumor cell membrane staining.The clinical data of patients were retrospective collected. The multivariate analysis was used to assess the association of PD-L1 expressionwith tumor staging, pathological N classification, whether firstly diagnosed with metastasis, disease free survival(DFS) and overall survival (OS) in patients. Results: The positive rates of PD-L1 expression were 42.3% (33/78) for upper tract urothelial carcinoma. Sex,location, pathological tumor staging, pathological N classification, whether firstly diagnosed with metastasis did not correlate with PD-L1 expression. In patients with upper tract UC, PD-L1 expression was not associated with DFS and OS on univariate analyses. Conclusions: To our knowledge, this is first study about PD-L1 expression in UTUC patients. In this study, We found the PD-L1 expression in UTUC was higher than in the bladder urothelial carcinoma. It means anti-PD-L1 treatment may be better for advanced UTUC. There was no correlation between PD-L1 expression and outcome.

The association of an exosomal form of PD-L1 with immunosuppressive activity and gastric cancer prognosis.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 47-47
Author(s):  
Yibo Fan ◽  
Xiaofang Che ◽  
Zhi Li ◽  
Xiujuan Qu ◽  
Yunpeng Liu
Keyword(s):  
Gastric Cancer ◽  
Cell Membrane ◽  
Tumor Cell ◽  
Cancer Cells ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Gastric Cancer Cell ◽  
Tumor Cell Membrane ◽  
Gastric Cancer Cell Lines ◽  
Gastric Cancer Patients

47 Background: The greatest challenge in cancer immunotherapy is to identify efficient predictive biomarkers to select patients for treatment. Though tumor cell membrane PD-L1 has been most anticipated, tumor cell membrane PD-L1 does not correlate with higher response rates and predict for clinical benefit. Subsequently studies showed that the prognostic value of tumor cell membrane PD-L1 in cancer patients remains controversial. In addition to membrane-associated PD-L1, tumor cell also secreted extracellular soluble PD-L1 in the microenvironment. However, even if extracellular soluble PD-L1 was detected, it did not solve the problem mentioned above. In the present study, we discovered another form of PD-L1 in extracellular microenvironment in cancer cells, that is exosomal PD-L1. However, the predictive role and the effect of tumor-derived exosomal PD-L1 is unclear. Methods: We evaluated the prognostic value of exosomal PD-L1 in the plasma of gastric cancer patients by ELISA and the effect of exosomal PD-L1-derived from gastric cancer cell lines by Western blot and Flow cytometry analysis. Results: Exosomal PD-L1 was detected in plasma samples from 69 gastric cancer patients, and exosomal PD-L1 content was significantly associated with T stage (P = 0.012). Overall Survival was significantly lower in the high exosomal PD-L1 group (p = 0.021). Additionally, gastric cancer cells also secreted exosomal PD-L1, with the amounts positively associated with PD-L1 amounts in the corresponding gastric cancer cell lines. Besides, exosomal PD-L1 was more stable and showed stronger immunosuppressive effects in the microenvironment compared with soluble PD-L1. Conclusions: Exosomal PD-L1 might predict the survival in gastric cancer, and induces higher T-cell apoptosis levels compared with soluble PD-L1.

scholarly journals A computational model for tumor cell membrane tolerance and rigidy limits

2011 ◽  
Author(s):  
George I. Lambrou ◽  
Apostolos Zaravinos ◽  
Maria Adamaki ◽  
Dimitrios Delakas ◽  
Spiros Vlahopoulos
Keyword(s):  
Cell Membrane ◽  
Tumor Cell ◽  
Computational Model ◽  
Tumor Cell Membrane

scholarly journals RGD4C Peptide Mediates anti-p21Ras scFv Entry Into Tumor Cells and Produces an Inhibitory Effect on the Human Colon Cancer Cell Line SW480

2020 ◽  
Author(s):  
Chenchen Huang ◽  
Fangrui Liu ◽  
Qiang Feng ◽  
Xinyan Pan ◽  
Shuling Song ◽  
...  
Keyword(s):  
Cell Membrane ◽  
Tumor Cell ◽  
Tumor Cells ◽  
Recombinant Expression ◽  
Cancer Cell Line ◽  
Human Colon ◽  
Inhibitory Effect ◽  
Human Colon Cancer ◽  
Tumor Cell Membrane ◽  
Sw480 Cells

Abstract BackgroundAn anti-p21Ras scFv can specifically bind with mutant and wild-type p21Ras but cannot penetrate the cell membrane, which prevents it from binding to p21Ras in the cytoplasm. Here, the RGD4C peptide was used to mediate scFv penetration into tumor cells and produce an inhibitory effect.MethodsRGD4C-linker-EGFP and RGD4C-p21Ras-scFv recombinant expression plasmids were constructed, and the fusion proteins were expressed in E. coli and purified with HisPur Ni-NTA. RGD4C-linker-EFGP was used to test the factors affecting RGD4C penetration of the tumor cell membrane. The immunoreactivity of RGD4C-p21Ras-scFv toward p21Ras was identified by ELISA and western blotting. Moreover, immunocytochemistry was used to detect the ability of RGD4C-p21Ras-scFv to penetrate SW480 cells. Cell migration, colony formation, cell killing, and apoptosis assays were used to assess the inhibitory effect of RGD4C-p21Ras-scFv on SW480 cells in vitro.ResultsThe RGD4C peptide could target tumor cells, but endocytosis inhibitors and a low temperature inhibited RGD4C peptide endocytosis into cells, and tumor cell entry was time and concentration dependent. Additionally, a change in the cell membrane potential did not affect penetrability. We found that RGD4C-p21Ras-scFv could penetrate SW480 cells; effectively inhibit the growth, proliferation and migration of SW480 cells; and promote apoptosis in SW480 cells. ConclusionThe RGD4C peptide can mediate anti-p21Ras scFv entry into SW480 cells and produce an inhibitory effect, which indicates that RGD4C-p21Ras-scFv may be a potential therapeutic antibody for the treatment of RAS-mutant colorectal cancer.

Sign in / Sign up

Export Citation Format

Share Document